Europe Bladder Cancer Therapeutics and Diagnostics Market

Europe Bladder Cancer Therapeutics And Diagnostics Market Analysis

The Europe Bladder Cancer Therapeutics and Diagnostics Market is expected to register a CAGR of 5% during the forecast period.

• The COVID-19 pandemic significantly impacted the Europe bladder cancer therapeutics and diagnostics market. For instance, according to the study published by IOS Press, in June 2022, the share of bladder cancer diagnoses fell by 14% during the first COVID wave in the Netherlands. Treatment-related alterations were kept to a minimum and adhered to the revised guidelines. As a result of the pandemic, the market for bladder cancer therapeutics and diagnostics was significantly impacted.
• However, the sector has been recovering since restrictions were lifted, resulting in the return of the normal pre-pandemic demand levels for therapeutic and diagnostic procedures. Thus, the Europe bladder cancer therapeutics and diagnostics market is expected to grow over the forecast period.
• Factors driving the market growth include increasing awareness of bladder diseases and available therapies, increasing the burden of bladder cancer, and innovations in drug development. For instance, according to an article published by the European Federation of Pharmaceutical Industries and Associations (EFPIA), in May 2022, bladder cancer is one of Europe's top 5 most common cancers, claiming more than 67,000 lives every year.
• Furthermore, in May 2022, Bladder Cancer Awareness Month (BCAM) was recognized by EFPIA, providing an important opportunity for the bladder cancer community to come together and shine a spotlight. As per the event, around 151,000 Europeans are diagnosed with bladder cancer yearly, making it the fifth most frequent cancer diagnosis on the continent and the second most common urological cancer. Hence, with the growing burden of bladder cancer, the demand for its diagnosis and treatment is expected to increase, thereby boosting the market growth.
• Additionally, various strategies adopted by the key market players, such as product launches and mergers and acquisitions, are anticipated to increase the demand for bladder cancer therapeutics and diagnostics, thereby driving market growth over the forecast period.
• For instance, in April 2022, Astellas Pharma Inc. and Seagen Inc. received the European Commission (EC) approval for PADCEV (enfortumab vedotin) as monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received platinum-containing chemotherapy and a PD-1/L1 inhibitor. The EC approval is supported by data from the global phase 3 EV-301 trial that demonstrated an overall survival (OS) benefit compared with chemotherapy.
• Therefore, the factors mentioned above, such as increasing awareness of bladder diseases and available therapies, increasing burden of bladder cancer, and innovations in drug development, are attributed collectively to the studied market growth over the forecast period. However, the rise in patent expirations is the primary factor restraining the market's growth.

Europe Bladder Cancer Therapeutics And Diagnostics Market Trends

Immunotherapy Segment is Expected to Show Better Growth in the Forecast period.

• Immunotherapy is a therapy that uses drugs to suppress or stimulate the immune system to help the body fight against bladder cancer. It relates to biological therapy for cancer treatment to boost the body's natural defenses to fight cancer. The advantages of immunotherapy over chemotherapy in a bladder cancer patient and product launches by the key market players drive the segment.
• For instance, according to an article published by Health Union, LLC, in February 2023, immunotherapies alert and train a person's immune system to identify and destroy cancer cells. Immunotherapy continues working even after the treatment period ends. In contrast, chemotherapy kills cancer and healthy cells while the drugs are in a person's body. The advantage of immunotherapy over chemotherapy is expected to drive the segment demand over the forecast period.
• Various strategies adopted by the key market players support the market growth over the forecast period. For instance, in January 2021, the European Commission approved nivolumab (Bavencio) as a frontline maintenance option in treating adult patients with locally advanced or metastatic urothelial carcinoma who did not progress after having received platinum-based chemotherapy.
• Avelumab is the immunotherapy to demonstrate a significant improvement in overall survival in the setting in a phase 3 study in advanced or metastatic bladder cancer. Thus, all factors above are expected to post the segment growth over the forecast period.

Germany is Expected to Hold a Significant Share of the Market Over the Forecast Period

• Germany holds a significant share due to the rise in the burden of bladder cancer, the presence of many companies, and the tremendous growth of bladder cancer therapeutics and diagnostics in the region. For instance, according to an article published by Deutsches Ärzteblatt International in October 2021, bladder carcinomas account for 3-4% of all malignant tumors in Germany. They occur at the age peak over 70 years. Bladder cancer is the fourth most common tumor in men in Germany and 14th in women.
• Furthermore, according to an article published by Booking Health GmbH in November 2022, bladder cancer ranks fourth in Germany amongst other oncology cases. Moreover, in Germany, about 15,000 patients are diagnosed with bladder cancer annually, which urges German medicine to develop the bladder cancer field of oncology. Thus, the increasing burden of bladder cancer due to the rise in the geriatric population in Germany is anticipated to increase the demand for bladder cancer therapeutics and diagnostics, thereby propelling the market growth.
• Additionally, various strategies adopted by the key market players support the market growth over the forecast period. For instance, in November 2022, Immutep Limited signed a Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany, and Pfizer for a new Phase I clinical study in patients with urothelial cancer called INSIGHT-005. Thus, all factors above are expected to boost the market growth in Germany over the forecast period.

Europe Bladder Cancer Therapeutics And Diagnostics Industry Overview

The Europe bladder cancer therapeutics and diagnostics market is moderately concentrated in nature due to the presence of companies operating in Europe. The competitive landscape includes an analysis of companies including AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Novartis, Pfizer Inc., and Sanofi SA, among others.

Europe Bladder Cancer Therapeutics And Diagnostics Market Leaders

Europe Bladder Cancer Therapeutics And Diagnostics Market News

• November 2022: Immutep Limited signed a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany, and Pfizer for a new Phase I clinical study in patients with urothelial cancer called INSIGHT-005. INSIGHT-005 will be an investigator-initiated explorative, open-label study evaluating the safety and efficacy of Immutep's lead product candidate, eftilagimod alpha (EFTI), in combination with avelumab (BAVENCIO) in up to 30 patients with metastatic urothelial cancer.
• April 2022: Bristol Myers Squibb approved Opdivo (nivolumab) by the European Commission (EC) for the adjuvant treatment of adults with muscle-invasive urothelial carcinoma with tumor cell PD-L1 expression 1% who are at a high risk of recurrence after undergoing radical resection.